AMGEN

Active

Public limited companyfounded 198936 yrs activeTelecomlaan 5-7, 1831 Machelen (Brab.), BelgiumKBO/BCE: BE 0439.652.401

Summary

AMGEN has been active since 1989 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €6.8m and a net result of €6.0m. Equity is shrinking by ~5.2% per year across the filed fiscal years. Its solvency ranks better than 17% of 4926 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).

Risk analysis Watch Report Compare

AMGENActiveChecked score 57/100

Risk analysis Report Compare

Checked score

Score 2025

57 / 100

Fair

Every signal that weighs is under Signals.

Axes · tick = 2024

Profitability69▼-2

Solvency40=

Growth71▲+1

Track record100

Bankruptcy probability, 12 months

0.2% Very low

0%0.5%1.5%4%10%≥ 25%

Credit up to €380,000 at 30 days acceptable

Liquidity tight (current ratio 1.29 against 1.27 in 2024; short-term debt: 76.2% and cash: 0% of total assets), and 85.1% of the assets are financed with debt.

Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Six signals. The signal on the left, the evidence on the right.

−lowers risk+raises risk○neutral

Long track record

A company with a long track record statistically fails less often than a young one.

KBO · incorporation date

Age against the risk zone

Annual accounts: healthy financial profile

The latest annual accounts show a healthy profile in solvency, result and liquidity.

NBB · annual accounts 2025

Solvency, return and age of the figures

Solvency

14.9%

Return on assets

13%

Age of the figures

9 mo

Lower-risk legal form

Companies with this legal form statistically fail less often than a BV.

KBO · legal form

Higher-failure-rate sector

In this sector companies fail more often than the Belgian average.

Gazette · bankruptcies per sector, NACE 46

Relative position

BE, all sectors

reference

Wholesale trade (NACE 46)

about 21% more bankruptcies

← fewer bankruptcies more bankruptcies →

Weak solvency vs sector

Solvency (equity / total assets) is in the sector's weakest quartile: better than 17% of 4926 sector peers (2025).

NBB · sector comparison

Position among 4926 sector peers

Solvency

better than 17%

← weakest strongest →

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 03-07-2026, 28 days ahead of the deadline.

NBB · 10 filings

Deviation from the deadline

2025

28 d early

2024

37 d early

2023

33 d early

2022

33 d early

2021

3 d early

2020

115 d late

2019

14 d early

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 5 days before the deadline; the sector median for financial year 2024 is 3 days before the deadline, and 39% of the sector filed late.

Checked, nothing found (2)

The next deadline is still running

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.

Companies Code · seven months

Position in the running window

28-09-2026 today31-12-2026 close31-07-2027 deadline

No strike-offs in the KBO publications

We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

KBO publications · our coverage

History

On 21 December 1989, AMGEN was incorporated.¹ In 2018 the registered office moved to Diegem.² Of the 4 current board members, Paraskevi Florou has served longest, since 2023.³ Revenue went from EUR 119 million in 2018 to EUR 196 million in 2025 and headcount from 98.1 to 94.7 full-time equivalents.⁴

Go further with this company

How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What other support did companies like this one receive, and it did not?Public money How does this company compare with its sector?Sector benchmark

Is this your company? See how customers and banks see it.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2025, full schema

Turnover

€195.9m▲ 11.6%

2024 · €175.6m

EBIT margin

3.8%▼ 0.8pp

2024 · 4.6%

Net result

€6.0m▲ 5.5%

2024 · €5.6m

Working capital

€10.1m▲ 22.0%

2024 · €8.3m

Trend over the years

Chart Table

Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 46, Wholesale trade, each year against the same schema; no band under 30 filings. Dashed line: the median.

Every figure with its change against the fiscal year before

favourable unfavourable

Line20212022202320242025

Turnover€139.3m▲ 8.1%€144.6m▲ 3.8%€147.1m▲ 1.8%€175.6m▲ 19.3%€195.9m▲ 11.6%

Operating result€5.6m▲ 4.5%€6.2m▲ 11.6%€6.0m▼ 4.1%€8.0m▲ 34.9%€7.4m▼ 8.3%

Net result€3.5m▼ 6.6%€5.0m▲ 43.3%€4.5m▼ 10.0%€5.6m▲ 26.2%€6.0m▲ 5.5%

EBIT margin4.0%▼ 0.1pp4.3%▲ 0.3pp4.1%▼ 0.2pp4.6%▲ 0.5pp3.8%▼ 0.8pp

Equity€16.3m▲ 27.0%€8.3m▼ 49.3%€7.7m▼ 6.4%€5.9m▼ 24.1%€6.8m▲ 16.2%

Total assets€52.3m▼ 4.1%€46.2m▼ 11.6%€41.2m▼ 10.9%€39.4m▼ 4.5%€45.6m▲ 15.9%

Debt€35.9m▼ 13.6%€38.0m▲ 5.8%€33.5m▼ 11.8%€32.2m▼ 3.9%€37.3m▲ 15.7%

Working capital€21.8m▲ 22.2%€14.5m▼ 33.5%€9.8m▼ 32.1%€8.3m▼ 16.0%€10.1m▲ 22.0%

Solvency31.1%▲ 7.6pp17.9%▼ 13.3pp18.7%▲ 0.9pp14.9%▼ 3.8pp14.9%=

Staff (FTE)94.7▼ 4.7%99.1▲ 4.6%100.3▲ 1.2%97.7▼ 2.6%94.7▼ 3.1%

above within below the middle half (P25 to P75) of NACE 46, Wholesale trade, each year against the same schema; no band under 30 filings.

Result per fiscal year

Operating resultNet result

The operating result falls in 2025; 2025 is 8% below 2024.

Balance-sheet composition

2025 in colour, 2024 as the grey bar beneath

Assets €45.6m

98.3%

Fixed assets €757,771 ▼ 15.7%

Current assets €44.9m ▲ 16.7%

Equity and liabilities €45.6m

14.9%

81.6%

Equity €6.8m ▲ 16.2%

Provisions €1.6m ▲ 19.4%

Debt €37.3m ▲ 15.7%

Debt's share of the balance-sheet total falls from 81.8% to 81.6%. Equity and debt are higher.

Key figures and ratios

2025 value · change against 2024

EBITDA

€7.6m▼

2024 · €8.1m

Cash flow

€6.1m▲

2024 · €5.7m

Current ratio

1.29▲

2024 · 1.27

Debt to equity

5.46▼

2024 · 5.49

ROE

87.3%▼

2024 · 96.1%

ROA

13.0%▼

2024 · 14.3%

Interest coverage

56.22▼

2024 · 63.10

Debt ≤ 1 year

€34.8m▲

2024 · €30.2m

Income taxes

€1.7m▼

2024 · €3.0m

Staff costs

€19.1m▲

2024 · €19.0m

Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 373 companies that looked in July 2024 the way this one looks now, 0.3% went bankrupt within 24 months and 97% are still going.

Medium-sized
20 years or older
solvency 10 to 30%
a profit of 5% of the balance sheet or more

0.3% went bankrupt

2.7% stopped otherwise

97% still going

For this company itself Checked computes a bankruptcy probability of 0.2% over twelve months; the group does not contradict it.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,058 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.

The companies in ten equal groups, from lowest to highest expected share.
Group	Expected	Actual
1	0.2%	0.2%
2	0.3%	0.4%
3	0.5%	0.5%
4	0.6%	0.7%
5	0.8%	0.9%
6	1.2%	1.3%
7	1.5%	1.6%
8	1.7%	1.7%
9	2.7%	2.8%
10	5.3%	5.7%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 373 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts

OverviewIncome statement Balance sheet Cash flow

Filed annual accounts As filed with the NBB · 2025 against 2024 · 63 lines

Balance sheet Code20242025

Assets

Total assets20/58€39.4m€45.6m▲

Fixed assets21/28€898,684€757,771▼

Tangible fixed assets22/27€898,684€757,771▼

Plant, machinery and equipment23€41,487€42,986▲

Furniture and vehicles24€92,698€62,478▼

Other tangible fixed assets26€725,716€642,699▼

Assets under construction and advance payments27€38,783€9,607▼

Current assets29/58€38.5m€44.9m▲

Amounts receivable within one year40/41€38.4m€44.8m▲

Trade receivables40€31.1m€31.4m▲

Other amounts receivable41€7.4m€13.4m▲

Cash at bank and in hand54/58€1,222€2,667▲

Deferred charges and accrued income490/1€27,500€53,835▲

Equity and liabilities

Total equity and liabilities10/49€39.4m€45.6m▲

Equity10/15€5.9m€6.8m▲

Contributions10/11€173,525€173,525=

Capital10€173,525€173,525=

Issued capital100€173,525€173,525=

Reserves13€17,353€17,353=

Non-distributable reserves130/1€17,353€17,353=

Legal reserve130€17,353€17,353=

Profit (loss) carried forward14€5.7m€6.6m▲

Provisions and deferred taxes16€1.3m€1.6m▲

Provisions for liabilities and charges160/5€1.3m€1.6m▲

Other liabilities and charges164/5€1.3m€1.6m▲

Amounts payable17/49€32.2m€37.3m▲

Amounts payable within one year42/48€30.2m€34.8m▲

Trade debts44€26.7m€30.9m▲

Suppliers440/4€26.7m€30.9m▲

Taxes, remuneration and social security45€3.5m€3.9m▲

Taxes450/3-€192,442

Remuneration and social security454/9€3.5m€3.7m▲

Accrued charges and deferred income492/3€2.0m€2.5m▲

Income statement Code20242025

Operating income70/76A€177.8m€198.4m▲

Turnover70€175.6m€195.9m▲

Other operating income74€2.3m€2.4m▲

Operating charges60/66A€169.8m€191.0m▲

Goods for resale, raw materials and consumables60€104.6m€111.1m▲

Purchases600/8€104.6m€111.1m▲

Services and other goods61€15.6m€18.3m▲

Remuneration, social security and pensions62€19.0m€19.1m▲

Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€32,209€177,736▲

Provisions for liabilities and charges: additions (uses and reversals)635/8€1.1m€252,826▼

Other operating charges640/8€29.5m€42.0m▲

Operating profit (loss)9901€8.0m€7.4m▼

Financial income75/76B€720,284€401,894▼

Recurring financial income75€720,284€401,894▼

Income from current assets751€720,284€401,894▼

Financial charges65/66B€176,804€135,218▼

Recurring financial charges65€176,804€135,218▼

Debt charges650€128,037€134,455▲

Other financial charges652/9€48,767€762▼

Profit (loss) for the period before taxes9903€8.6m€7.6m▼

Income taxes67/77€3.0m€1.7m▼

Taxes670/3€3.0m€2.1m▼

Tax adjustments and reversals of tax provisions77-€353,387

Profit (loss) for the period9904€5.6m€6.0m▲

Profit (loss) for the period to be appropriated9905€5.6m€6.0m▲

Appropriation of the result

Profit (loss) to be appropriated9906€13.2m€11.6m▼

Profit (loss) brought forward from the previous period14P€7.5m€5.7m▼

Profit to be distributed694/7€7.5m€5.0m▼

Return on contributions (dividend)694€7.5m€5.0m▼

Social balance

Average headcount (FTE)908797.794.7▼

The notes to these accounts (43 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line	2021	2022	2023	2024	2025	Change
Operating income70/76A	€141.4m	€146.9m	€149.4m	€177.8m	€198.4m	▲ 11.6%
Turnover70	€139.3m	€144.6m	€147.1m	€175.6m	€195.9m	▲ 11.6%
Other operating income74	€2.1m	€2.3m	€2.3m	€2.3m	€2.4m	▲ 7.8%
Operating charges60/66A	€135.8m	€140.7m	€143.5m	€169.8m	€191.0m	▲ 12.5%
Goods for resale, raw materials and consumables60	€95.2m	€96.3m	€99.5m	€104.6m	€111.1m	▲ 6.2%
Purchases600/8	€95.2m	€96.3m	€99.5m	€104.6m	€111.1m	▲ 6.2%
Services and other goods61	€14.3m	€14.9m	€14.8m	€15.6m	€18.3m	▲ 17.8%
Remuneration, social security and pensions62	€16.5m	€17.7m	€18.3m	€19.0m	€19.1m	▲ 0.9%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630	€154,392	€124,438	€192,021	€32,209	€177,736	▲ 452%
Provisions for liabilities and charges: additions (uses and reversals)635/8	-€73,792	-€100,625	€0	€1.1m	€252,826	▼ 77.9%
Other operating charges640/8	€9.8m	€11.9m	€10.8m	€29.5m	€42.0m	▲ 42.5%
Operating profit (loss)9901	€5.6m	€6.2m	€6.0m	€8.0m	€7.4m	▼ 8.3%
Financial income75/76B	-	€79,155	€664,562	€720,284	€401,894	▼ 44.2%
Recurring financial income75	-	€79,155	€664,562	€720,284	€401,894	▼ 44.2%
Income from current assets751	-	-	€664,562	€720,284	€401,894	▼ 44.2%
Other financial income752/9	-	€79,155	-	-	-	-
Financial charges65/66B	€81,262	€137,912	€117,797	€176,804	€135,218	▼ 23.5%
Recurring financial charges65	€81,262	€137,912	€117,797	€176,804	€135,218	▼ 23.5%
Debt charges650	€50,799	€109,954	€117,637	€128,037	€134,455	▲ 5.0%
Other financial charges652/9	€30,463	€27,958	€160	€48,767	€762	▼ 98.4%
Profit (loss) for the period before taxes9903	€5.5m	€6.2m	€6.5m	€8.6m	€7.6m	▼ 11.0%
Income taxes67/77	€2.0m	€1.2m	€2.0m	€3.0m	€1.7m	▼ 42.5%
Taxes670/3	€2.0m	€1.4m	€2.0m	€3.0m	€2.1m	▼ 30.5%
Tax adjustments and reversals of tax provisions77	-	€247,108	-	-	€353,387	-
Profit (loss) for the period9904	€3.5m	€5.0m	€4.5m	€5.6m	€6.0m	▲ 5.5%
Profit (loss) for the period to be appropriated9905	€3.5m	€5.0m	€4.5m	€5.6m	€6.0m	▲ 5.5%

Line	2021	2022	2023	2024	2025	Change
Assets
Total assets20/58	€52.3m	€46.2m	€41.2m	€39.4m	€45.6m	▲ 15.9%
Fixed assets21/28	€857,369	€771,942	€793,734	€898,684	€757,771	▼ 15.7%
Tangible fixed assets22/27	€857,369	€771,942	€793,734	€898,684	€757,771	▼ 15.7%
Plant, machinery and equipment23	€92,854	€83,385	€58,763	€41,487	€42,986	▲ 3.6%
Furniture and vehicles24	€226,705	€171,092	€129,109	€92,698	€62,478	▼ 32.6%
Other tangible fixed assets26	€515,084	€511,514	€546,235	€725,716	€642,699	▼ 11.4%
Assets under construction and advance payments27	€22,726	€5,951	€59,628	€38,783	€9,607	▼ 75.2%
Current assets29/58	€51.4m	€45.5m	€40.4m	€38.5m	€44.9m	▲ 16.7%
Amounts receivable within one year40/41	€51.2m	€45.5m	€40.4m	€38.4m	€44.8m	▲ 16.6%
Trade receivables40	€27.9m	€34.1m	€30.6m	€31.1m	€31.4m	▲ 1.0%
Other amounts receivable41	€23.4m	€11.3m	€9.8m	€7.4m	€13.4m	▲ 82.4%
Cash at bank and in hand54/58	-	€1,222	€1,913	€1,222	€2,667	▲ 118%
Deferred charges and accrued income490/1	€212,639	€22,620	€24,768	€27,500	€53,835	▲ 95.8%
Equity and liabilities
Total equity and liabilities10/49	€52.3m	€46.2m	€41.2m	€39.4m	€45.6m	▲ 15.9%
Equity10/15	€16.3m	€8.3m	€7.7m	€5.9m	€6.8m	▲ 16.2%
Contributions10/11	€173,525	€173,525	€173,525	€173,525	€173,525	=
Capital10	€173,525	€173,525	€173,525	€173,525	€173,525	=
Issued capital100	€173,525	€173,525	€173,525	€173,525	€173,525	=
Reserves13	€17,353	€17,353	€17,353	€17,353	€17,353	=
Non-distributable reserves130/1	€17,353	€17,353	€17,353	€17,353	€17,353	=
Legal reserve130	€17,353	€17,353	€17,353	€17,353	€17,353	=
Profit (loss) carried forward14	€16.1m	€8.1m	€7.5m	€5.7m	€6.6m	▲ 16.8%
Provisions and deferred taxes16	€104,549	€3,924	€3,924	€1.3m	€1.6m	▲ 19.4%
Provisions for liabilities and charges160/5	€104,549	€3,924	€3,924	€1.3m	€1.6m	▲ 19.4%
Other liabilities and charges164/5	€104,549	€3,924	€3,924	€1.3m	€1.6m	▲ 19.4%
Amounts payable17/49	€35.9m	€38.0m	€33.5m	€32.2m	€37.3m	▲ 15.7%
Amounts payable within one year42/48	€29.7m	€31.0m	€30.6m	€30.2m	€34.8m	▲ 15.2%
Trade debts44	€25.0m	€27.5m	€26.9m	€26.7m	€30.9m	▲ 15.6%
Suppliers440/4	€25.0m	€27.5m	€26.9m	€26.7m	€30.9m	▲ 15.6%
Taxes, remuneration and social security45	€4.6m	€3.5m	€3.7m	€3.5m	€3.9m	▲ 11.8%
Taxes450/3	€558,429	€62,470	-	-	€192,442	-
Remuneration and social security454/9	€4.1m	€3.4m	€3.7m	€3.5m	€3.7m	▲ 6.2%
Accrued charges and deferred income492/3	€6.2m	€7.0m	€2.9m	€2.0m	€2.5m	▲ 23.7%

Line	2021	2022	2023	2024	2025	Change
Profit (loss) for the period9904	€3.5m	€5.0m	€4.5m	€5.6m	€6.0m	▲ 5.5%
+ Depreciation and write-downs630	€154,392	€124,438	€192,021	€32,209	€177,736	▲ 452%
Operating cash flow (approximation)	€3.6m	€5.1m	€4.7m	€5.7m	€6.1m	▲ 8.1%
Investment in fixed assets (approximation)	-	-€39,011	-€213,813	-€137,159	-€36,823	▲ 73.2%
Change in cash	-	-	€691	-€691	€1,445	▲ 309%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

All 34Financial 2Gazette 22Filings 10

Next filing, fiscal year 2026, expected by 31-07-2027

2026

17-09

State Gazette act Appointment: Djihane Djouama (director)

Power of attorney9 facts ▸

General meeting, 27-07-2026
Director appointment, Djihane Djouama (director)
Board composition, Roman Stampfli (director)
Board composition, Sara Schaufelberger (director)
Board composition, Paraskevi Florou (director)
Board composition, Djihane Djouama (director)
Power of attorney, Yannick Stemotte
Power of attorney, Guillaume Nelis
Power of attorney

03-07

NBB filing Annual accounts filed

fiscal year 2025 · full schema

2025

31-12

Financial Highest result since 2018net €6.0m ▲5.5%

Net result €6.0m, the highest in the series.

17-11

State Gazette act Resignation: Heba Elmorshedy (director)

5 facts ▸

General meeting, 13-10-2025
Director resignation, Heba Elmorshedy (director)
Board composition, Roman Stampfli (director)
Board composition, Sara Schaufelberger (director)
Board composition, Paraskevi Florou (director)

24-06

NBB filing Annual accounts filed

fiscal year 2024 · full schema

2024

21-11

State Gazette act Appointments: ELMORSHEDY Heba Amgad (director) and SCHAUFELBERGER Sara Andrea (director)

Statutes amendment · Director discharge · Capital8 facts ▸

General meeting, 07-11-2024
Statutes amendment
Director discharge, AMGEN
Capital, €173.525,46
Director appointment, ELMORSHEDY Heba Amgad (director)
Director appointment, SCHAUFELBERGER Sara Andrea (director)
Mandate compensation, ELMORSHEDY Heba Amgad
Mandate compensation, SCHAUFELBERGER Sara Andrea

02-10

State Gazette act Resignation: Gabor Sztaniszlav (director)

Director discharge · Power of attorney6 facts ▸

General meeting, 20-08-2024
Director resignation, Gabor Sztaniszlav (director)
Director discharge, Gabor Sztaniszlav
Board composition, Roman Stampfli (director)
Board composition, Paraskevi Florou (director)
Power of attorney, Simmons & Simmons LLP

05-09

State Gazette act Resignation: Gwenaël Caesens (director)

Appointment: Roman Stampfli (director) · Director discharge · Power of attorney13 facts ▸

General meeting, 28-06-2024
Director resignation, Gwenaël Caesens (director)
Director discharge, Gwenaël Caesens
Board composition, Gabor Sztaniszlav (managing director)
Board composition, Paraskevi Florou (director)
Power of attorney, Simmons & Simmons LLP
General meeting, 11-07-2024
Director appointment, Roman Stampfli (director)
Mandate compensation, Roman Stampfli
Board composition, Gabor Sztaniszlav (managing director)
Board composition, Paraskevi Florou (director)
Board composition, Roman Stampfli (director)
+1 further facts in this act

28-06

NBB filing Annual accounts filed

fiscal year 2023 · full schema

2023

28-06

NBB filing Annual accounts filed

fiscal year 2022 · full schema

05-06

State Gazette act Resignation: Adam Stewart Elinoff (director)

Appointment: Paraskevi Florou (director) · Director discharge · Mandate compensation9 facts ▸

General meeting, 28-04-2023
Director resignation, Adam Stewart Elinoff (director)
Director discharge, Adam Stewart Elinoff
Director appointment, Paraskevi Florou (director)
Mandate compensation, Paraskevi Florou
Board composition, Gabor Sztaniszlav (managing director)
Board composition, Gwenaël Caesens (director)
Board composition, Paraskevi Florou (director)
Power of attorney, Simmons & Simmons LLP

2022

28-07

NBB filing Annual accounts filed

fiscal year 2021 · full schema

Show earlier events

2021

23-11

NBB filing Annual accounts filed

fiscal year 2020 · full schema · 115 days late

2020

31-12

Financial Equity above €10mEq €12.8m ▲40.7%

3 profitable years in a row build equity to €12.8m.

18-09

State Gazette act Reappointment: Ernst & Young Bedrijfsrevisoren (statutory auditor)

Permanent representative: Wim Van Gasse · Resignation: Catherine Boutremans (director) · Appointment: Gabor Sztaniszláv (director)19 facts ▸

General meeting, 18-08-2020
Auditor reappointment, Ernst & Young Bedrijfsrevisoren
Permanent representative, Wim Van Gasse
General meeting, 31-08-2020
Director resignation, Catherine Boutremans (director)
Director discharge, Catherine Boutremans
Director appointment, Gabor Sztaniszláv (director)
Mandate compensation, Gabor Sztaniszláv
Board meeting, 01-09-2020
Director resignation, Catherine Boutremans (managing director and chair)
Director appointment, Gabor Sztaniszláv (managing director)
Director appointment, Gabor Sztaniszláv (chair)
+7 further facts in this act

25-08

State Gazette act Resignations & appointments

Power of attorney3 facts ▸

Board meeting, 29-05-2020
Power of attorney, Mary Alice Lehmann
Power of attorney, Justin Claeys

17-07

NBB filing Annual accounts filed

fiscal year 2019 · full schema

05-03

State Gazette act Resignation: Justin Claeys (director)

Appointment: Adam Stewart Elinoff (director) · Director discharge · Mandate compensation5 facts ▸

General meeting, 10-02-2020
Director resignation, Justin Claeys (director)
Director discharge, Justin Claeys
Director appointment, Adam Stewart Elinoff (director)
Mandate compensation, Adam Stewart Elinoff

2019

11-12

State Gazette act Resignation: Virginie Saillard-Drouet (director)

Appointment: Gwenaël Caesens (director) · Director discharge · Mandate compensation10 facts ▸

General meeting, 07-11-2019
Director resignation, Virginie Saillard-Drouet (director)
Director discharge, Virginie Saillard-Drouet
Director appointment, Gwenaël Caesens (director)
Mandate compensation, Gwenaël Caesens
Power of attorney, Simmons & Simmons LLP
Board meeting, 07-11-2019
Power of attorney, Virginie Saillard-Drouet
Power of attorney, Gwenaël Caesens
Power of attorney, Simmons & Simmons LLP

31-07

NBB filing Annual accounts filed

fiscal year 2018 · full schema

20-03

State Gazette act Resignation: Corinne Buffet (director)

Appointment: Catherine Boutremans (director) · Director discharge · Mandate compensation19 facts ▸

General meeting, 08-02-2019
Board meeting, 08-02-2019
Director resignation, Corinne Buffet (director)
Director discharge, Corinne Buffet
Director appointment, Catherine Boutremans (director)
Mandate compensation, Catherine Boutremans
Director appointment, Catherine Boutremans (managing director)
Director appointment, Catherine Boutremans (chair of the board)
Board composition, Catherine Boutremans (director)
Board composition, Virginie Saillard-Drouet (director)
Board composition, Justin Claeys (director)
Power of attorney, Corinne Buffet
+7 further facts in this act

2018

27-12

State Gazette act Resignations & appointments

Power of attorney4 facts ▸

Board meeting, 10-12-2018
Power of attorney, Corinne Buffet
Power of attorney, Valery Fikkert
Power of attorney, Simmons & Simmons LLP

28-09

NBB filing Annual accounts filed

fiscal year 2017 · full schema · 59 days late

01-08

State Gazette act Resignations & appointments

Power of attorney9 facts ▸

Board meeting, 25-06-2018
Power of attorney, Corinne Buffet
Power of attorney, Virginie Saillard-Drouet
Power of attorney, Katrien Casteleyn
Power of attorney, Olivier Mignolet
Power of attorney, Annabelle Bruyndonckx
Power of attorney, Yannick Stemotte
Power of attorney, Michael Bulckaert
Power of attorney, Vladimir Murovec

13-06

State Gazette act Resignation: Christopher Ian McKinlay (director)

Appointment: CLAEYS Justin Gary (director) · Statutes amendment · Mandate compensation11 facts ▸

General meeting, 15-05-2018
Statutes amendment
Statutes amendment
Statutes amendment
Statutes amendment
Statutes amendment
Statutes amendment
Statutes amendment
Director resignation, Christopher Ian McKinlay (director)
Director appointment, CLAEYS Justin Gary (director)
Mandate compensation, CLAEYS Justin Gary

22-03

State Gazette act Registered office

Registered-office move2 facts ▸

Board meeting, 08/03/2018
Registered-office move, Telecomlaan 5-7, 1831 Diegem

2017

17-07

NBB filing Annual accounts filed

fiscal year 2016 · full schema

01-03

State Gazette act Permanent representative: Wim Van Gasse

Resignation: Yves Zinggeler (director) · Reappointments: Virginie Saillard-Drouet (director) and Christopher McKinlay (director) · Appointment: Corinne Buffet (director)20 facts ▸

General meeting, 01-02-2017
Board meeting, 01-02-2017
Permanent representative, Wim Van Gasse
Director resignation, Yves Zinggeler (director)
Director reappointment, Virginie Saillard-Drouet (director)
Director reappointment, Christopher McKinlay (director)
Director appointment, Corinne Buffet (director)
Mandate compensation, Virginie Saillard-Drouet
Mandate compensation, Christopher McKinlay
Mandate compensation, Corinne Buffet
Board composition, Virginie Saillard-Drouet (director)
Board composition, Christopher McKinlay (director)
+8 further facts in this act

2015

16-10

State Gazette act Reappointment: Ernst & Young Bedrijfsrevisoren (statutory auditor)

Permanent representative: Herman Van den Abeele · Resignation: Jean-Christophe Bencteux (director) · Appointment: Yves Zinggeler (director)13 facts ▸

General meeting, 22-09-2015
Board meeting, 22-09-2015
Auditor reappointment, Ernst & Young Bedrijfsrevisoren
Permanent representative, Herman Van den Abeele
Director resignation, Jean-Christophe Bencteux (director)
Director appointment, Yves Zinggeler (director)
Mandate compensation, Yves Zinggeler
Director resignation, Jean-Christophe Bencteux (managing director)
Director appointment, Yves Zinggeler (managing director)
Mandate compensation, Yves Zinggeler
Power of attorney, Tom Swinnen
Power of attorney, Mattias Verbeeck
+1 further facts in this act

2013

04-12

State Gazette act Resignations: Michael Aaron Kelly (director) and Thiel Frank Carsten (director)

Appointments: Virginie Saillard-Drouet (director) and Christopher McKinlay (director) · Mandate compensation · Statutes amendment8 facts ▸

General meeting, 06-11-2013
Director resignation, Michael Aaron Kelly (director)
Director resignation, Thiel Frank Carsten (director)
Director appointment, Virginie Saillard-Drouet (director)
Director appointment, Christopher McKinlay (director)
Mandate compensation, Virginie Saillard-Drouet
Mandate compensation, Christopher McKinlay
Statutes amendment

27-11

State Gazette act Resignations & appointments

Power of attorney5 facts ▸

Board meeting, 11-11-2013
Power of attorney, Mary Alice Lehmann
Power of attorney, Michel Bonne
Power of attorney, Tom Swinnen
Power of attorney, Marie Georgy

2012

05-11

State Gazette act Resignation: Rolf Karl-Heinz Hoffman (director)

Appointment: Frank Carsten Thiel (director) · Reappointments: Jean-Christophe Bencteux (director) and Ernst&Young Bedrijfsrevisoren (statutory auditor) · Permanent representative: Herman Van den Abeele13 facts ▸

General meeting, 02-10-2012
Director resignation, Rolf Karl-Heinz Hoffman (director)
Director appointment, Frank Carsten Thiel (director)
Mandate compensation, Frank Carsten Thiel
Director reappointment, Jean-Christophe Bencteux (director)
Board composition, Michael Aaron Kelly (director)
Board composition, Jean-Christophe Bencteux (director)
Board composition, Frank Carsten Thiel (director)
Auditor reappointment, Ernst&Young Bedrijfsrevisoren
Permanent representative, Herman Van den Abeele
Power of attorney, Tom Swinnen
Power of attorney, Michael Dirkx
+1 further facts in this act

2010

09-11

State Gazette act Resignations: Thomas Dittrich (director) and Giuseppe Trotta (gedelegeerd tot het dagelijks bestuur)

Appointment: Michael Aaron Kelly (director) · Reappointments: Ernst&Young Bedrijfsrevisoren (statutory auditor) and Rolf Karl-Heinz Hoffmann (director) · Mandate compensation13 facts ▸

General meeting, 14-10-2010
Director resignation, Thomas Dittrich (director)
Director appointment, Michael Aaron Kelly (director)
Mandate compensation, Michael Aaron Kelly
Statutes amendment
Statutes amendment
Auditor reappointment, Ernst&Young Bedrijfsrevisoren
Director reappointment, Rolf Karl-Heinz Hoffmann (director)
Power of attorney
Board meeting, 15-10-2010
Director resignation, Giuseppe Trotta (gedelegeerd tot het dagelijks bestuur)
Power of attorney
+1 further facts in this act

2009

22-06

State Gazette act Reappointment: Emst & Young Bedrijfsrevisoren (statutory auditor)

2 facts ▸

General meeting, 01-06-2007
Auditor reappointment, Emst & Young Bedrijfsrevisoren (statutory auditor)

Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

22 of 22 acts read

Directors · office · real estate

Directors

4 directors, no change since 2026

Paraskevi Florou

Director · since 01-04-2023

Current

Roman Stampfli

Director · since 11-07-2024

Current

SCHAUFELBERGER Sara Andrea

Director · since 07-11-2024

Current

Djihane Djouama

Director · since 27-07-2026

Current

3 not recently confirmed

Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.

Christopher McKinlay

Director · since 06-11-2013

Not recently confirmed

CLAEYS Justin Gary

Director · since 15-05-2018

Not recently confirmed

Rolf Karl-Heinz Hoffmann

Director

Not recently confirmed

Derived from published Gazette acts. The CBE keeps the official list of function holders; we do not read it, so the two can differ. See the function holders in the CBE →

Location & real-estate footprint

Registered office, Machelen (Brab.) · 1 establishment unit since 1990

seat establishment The establishment unit on the map

Ground area

7,487 m²

Building footprint

2,662 m²

Volume, LiDAR

49,226 m³

Parcel 23015B0030/00N000, Flanders · tallest building 23.2 m, ±6 floors. Linked by address, not a title deed.

1 establishment unit

Telecomlaan 5-7, 1831 Machelen (Brab.)

NACE 51460

since 19902.102.787.873

1 parcel

Flanders 1 (100%)

Parcel (capakey)	Region	Area	Buildings	Height / fl.
23015B0030/00N000	Flanders	7,487 m²	1 · 2,662 m²	23.2 m · 6 fl.

Linked by address, not proof of ownership

Good to know

1 of 1 parcel with an exact address match; the rest are indicative.

Linked through address data, this is not proof of ownership.

Mandate history

25 people since 2007, 7 in office

All 25 In office 7 Ended 18

Board
Day-to-day management
Statutory auditor
not recently confirmed
began earlier

Mandates per person, with start and end dates
Name	Functions and periods
Paraskevi Florou	Director, from 01-04-2023 to date
Roman Stampfli	Director, from 11-07-2024 to date
SCHAUFELBERGER Sara Andrea	Director, from 07-11-2024 to date
Djihane Djouama	Director, from 27-07-2026 to date
Rolf Karl-Heinz Hoffmann	Director, already before 09-11-2010 not ended, last confirmed 09-11-2010
Christopher McKinlay	Director, from 06-11-2013 not ended, last confirmed 01-03-2017
CLAEYS Justin Gary	Director, from 15-05-2018 not ended, last confirmed 13-06-2018
ELMORSHEDY Heba Amgad	Director, from 07-11-2024 to 03-09-2025
Gabor Sztaniszláv	Chair, from 01-09-2020 ended, last mentioned 18-09-2020 Director, from 01-09-2020 to 20-08-2024 Managing director, from 01-09-2020 ended, last mentioned 18-09-2020
Gwenaël Caesens	Director, from 07-11-2019 to 01-05-2024
Adam Stewart Elinoff	Director, from 29-02-2020 to 31-01-2023
Ernst et Young Reviseurs d'Entreprises	Auditor, from 30-06-2010 to 18-09-2020
Catherine Boutremans	Chair of the board, from 01-01-2019 ended, last mentioned 20-03-2019 Director, from 01-01-2019 to 01-09-2020 Managing director, from 01-01-2019 to 01-09-2020 Managing director and chair, until 01-09-2020
Justin Claeys	Director, until 29-02-2020
Virginie Saillard-Drouet	Director, from 06-11-2013 to 07-11-2019
Corinne Buffet	Director, from 25-01-2017 to 01-01-2019 Managing director, from 31-01-2017 ended, last mentioned 01-03-2017
Christopher Ian McKinlay	Director, until 15-05-2018
Yves Zinggeler	Director, from 30-09-2015 to 31-01-2017 Managing director, from 30-09-2015 to 31-01-2017
Jean-Christophe Bencteux	Director, already before 05-11-2012 to 30-09-2015 Managing director, until 30-09-2015
Michael Aaron Kelly	Director, from 01-10-2010 to 06-11-2013
Thiel Frank Carsten	Director, from 01-08-2012 to 06-11-2013
Rolf Karl-Heinz Hoffman	Director, until 31-07-2012
Giuseppe Trotta	Gedelegeerd tot het dagelijks bestuur, until 01-10-2010
Thomas Dittrich	Director, until 30-08-2010
Emst & Young Bedrijfsrevisoren	Statutory auditor, from 01-06-2007 to 30-06-2010

Show all 25 people Show the first 12See the board, name and seat on a given date →

Articles of association

Who signs

Two directors jointly

according to the deed of 17-09-2026

Purpose

Het onderzoek, de ontwikkeling, productie en de handel in farmaceutische producten

according to the deed of 21-11-2024

Structure & network

Owners and holdings

3 owners

Chain of control

Amgen Worldwide Holdings BVNL 99.99%
AMGEN

Highest known parent: Amgen Worldwide Holdings BV (Netherlands). The sources do not say who stands above it.

Owners 3

Amgen Worldwide Holdings BVNLparent

Sourceown accounts 2025

99.99%
AMGEN INC.USparent

SourceLEI register

consolidated
Amgen International AGCH

Sourceown accounts 2025

0.01%

Holdings 0

The accounts to 31-12-2025 list no holdings, and no other source names one.

According to the 2025 annual accounts of AMGEN and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.

Connections & network

4 current directors

Depth

The group is listed under Ownership & control below; here you explore it as a network.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, scroll to zoom.

Ownership & control

1 board mandate

Control over this companyparent company per the LEI register1

AMGEN INC.

Wilmington, United States

controls

AMGENBE 0439.652.401

Board mandates of this companythis company sits on their board1

ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE

1 location

Capital and shareholders

Capital over the years

21-11-2024 Capital stated in the act · 173,525.46 EUR · 7,000 shares

Public money · subsidies and aid

European Union, budget

2025 · 2 entries

Year	Entries	awarded
2025	2	0 EUR

Projects

GREG - TESTING, IMPROVING, AND CO-CREATING GUIDANCE AND TOOLS FOR REAL WORLD EVIDENCE GENERATION IN EUROPE AND USE FOR DECISION-MAKING IN EUROPE: GREG

Decentralised Agencies, Joint Undertakings, EU institutions · 01-05-2025 to 30-04-2030

UNIFIED - UNIFYING FRAMEWORK FOR PATIENT-CENTRED CLINICAL-STUDY ENDPOINTS DERIVED FROM DIGITAL HEALTH TECHNOLOGIES

Decentralised Agencies, Joint Undertakings, EU institutions · 01-11-2025 to 31-10-2030

European research

23 projects

Programmes

Horizon 2020

6 entries

Horizon Europe

5 entries

Seventh Framework Programme

12 entries

Projects

INDIVIDUALISED CARE FROM EARLY RISK OF CARDIOVASCULAR DISEASE TO ESTABLISHED HEART FAILURE

Horizon Europe · participant · 01-10-2023 to 31-03-2028 · iCARE4CVD

REpresentative Clinical Research - ADvancing Inclusivity in Europe

Horizon Europe · participant · 01-01-2025 to 31-12-2030 · READI

Synthetic hEalthcare dAta goveRnanCe Hub

Horizon Europe · participant · 01-10-2024 to 30-09-2028 · SEARCH

Testing, improving, and co-creating Guidance and Tools for Real World Evidence Generation in Europe and use for Decision-Making in Europe: GREG

Horizon Europe · participant · 01-05-2025 to 30-04-2030 · GREG

Unifying Framework for Patient-centred Clinical-study Endpoints derived from Digital Health Technologies

Horizon Europe · participant · 01-11-2025 to 31-10-2030 · UNIFIED

Show 18 more projects

Optimal treatment for patients with solid tumours in Europe through Artificial intelligence

Horizon 2020 · participant · 01-10-2021 to 30-09-2026 · OPTIMA

Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes - Sofia ref.: 115890

Horizon 2020 · participant · 01-07-2015 to 30-04-2018 · ADAPT-SMART

Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026

Horizon 2020 · participant · 01-01-2017 to 30-06-2023 · HARMONY

Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055

Horizon 2020 · participant · 01-02-2017 to 31-01-2019 · DO-IT

ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064

Horizon 2020 · participant · 01-01-2017 to 31-12-2023 · ITCC-P4

Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement

Horizon 2020 · participant · 01-04-2019 to 30-06-2024 · MOBILISE-D

SAFER AND FASTER EVIDENCE-BASED TRANSLATION

Seventh Framework Programme · participant · 15-06-2009 to 14-06-2015 · SAFE-T

Pharmacoepidemiolocal Research on Outcomes of Therapeutics by a European ConsorTium

Seventh Framework Programme · participant · 01-09-2009 to 30-04-2015 · PROTECT

Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes

Seventh Framework Programme · participant · 01-10-2009 to 30-09-2015 · U-BIOPRED

Pharmaceutical Medicine Training Programme

Seventh Framework Programme · participant · 01-05-2009 to 30-04-2014 · PHARMATRAIN

European programme in Pharmacovigilance and Pharmacoepidemiology

Seventh Framework Programme · participant · 01-09-2009 to 30-06-2016 · EU2P

QUantitative Imaging in Cancer: CONnecting CEllular Processes with Therapy

Seventh Framework Programme · participant · 01-09-2011 to 30-06-2018 · QUIC-CONCEPT

Electronic Health Record systems for Clinical Research

Seventh Framework Programme · participant · 01-03-2011 to 29-02-2016 · EHR4CR

European Patients' Academy on Therapeutic Innovation

Seventh Framework Programme · participant · 01-02-2012 to 31-01-2017 · EUPATI

European Medical Information Framework

Seventh Framework Programme · participant · 01-01-2013 to 30-06-2018 · EMIF

Incorporating real-life clinical data into drug development

Seventh Framework Programme · participant · 01-10-2013 to 31-03-2017 · GETREAL

Recognising Adverse Drug Reactions

Seventh Framework Programme · participant · 01-09-2014 to 31-12-2017 · WEB-RADR

European Prevention of Alzheimer’s Dementia Consortium

Seventh Framework Programme · participant · 01-01-2015 to 31-12-2019 · EPAD

Recognitions · licences · registrations

Legal Entity Identifier

5493007TDQLA2Z7RB387

no longer live in the LEI register

Similar companies · same sector, comparable size

BeMedico

BE 0432.727.589

Herzele · Eq €6,839,375

ELSCOLAB

BE 0421.938.518

Beveren-Kruibeke-Zwijndrecht · Eq €6,725,935

ixX pharma

BE 0873.490.740

Antwerpen · Eq €6,926,124

European Distribution Center Motiva

BE 0881.512.541

Wommelgem · Eq €6,926,725

Norgine

BE 0403.077.461

Leuven · Eq €6,956,923

Of 1,903 companies in sector 46460 we hold annual accounts for 1,126. 517 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Identification & contact

Identification

Legal formPublic limited company

Founded21-12-1989

Fiscal year end31-12

Activities, NACEBEL 2025

46460Wholesale of pharmaceutical and medical goods

E-invoicing

Reachable via Peppol

Peppol ID 0208:0439652401

Also 9925:BE0439652401

Registered 09-09-2025

Scores and ratios are computed by Checked and are not a credit decision.